DAX25.581 +2,2%Est506.360 +1,2%MSCI World4.343 -0,1%Top 10 Crypto7,9000 +0,1%Nas25.833 -0,8%Bitcoin53.836 ±-0,0%Euro1,1460 +0,3%Öl72,16 +0,8%Gold4.172 +1,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Bayer BAY001 Infineon 623100 SpaceX A42D4F Deutsche Telekom 555750 SAP 716460 Micron Technology 869020 NVIDIA 918422 Lufthansa 823212 Volkswagen (VW) vz. 766403 Siemens Energy ENER6Y BYD A0M4W9 Allianz 840400 Deutsche Bank 514000 Microsoft 870747
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX vor weiterer Rekordjagd -- Asiens Börsen mit Gewinnen -- Nur ein DAX-Konzern in den Top 100 im Börsenranking -- RENK wohl mit Übernahme -- Lufthansa, KION im Fokus
Top News
Aktien von Allianz und SAP fallen aus den Top 100, Siemens hält die Stellung: Deutschland bleibt ein Börsenzwerg Aktien von Allianz und SAP fallen aus den Top 100, Siemens hält die Stellung: Deutschland bleibt ein Börsenzwerg
RENK-Aktie mit nächstem Rüstungsdeal? Offenbar große Übernahme im Marinegeschäft geplant RENK-Aktie mit nächstem Rüstungsdeal? Offenbar große Übernahme im Marinegeschäft geplant
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Jazz Pharmaceuticals Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
212,30 EUR -0,30 EUR -0,14 %
STU
246,67 USD +3,38 USD +1,39 %
nachbörslich
BTT
finanzen.net zero
Jazz Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.13,06 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1JS1K

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINIE00B4Q5ZN47

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolJAZZ

Jazz Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireJazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference
PR NewswireJazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference
PR NewswireJazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
PR NewswireJazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma
PR NewswireJazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
PR NewswireJazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
PR NewswireJazz Pharmaceuticals Completes Acquisition of Chimerix
PR NewswireJazz Pharmaceuticals Completes Acquisition of Chimerix
PR NewswireJazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
PR NewswireJazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
PR NewswireJazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Aca...
PR NewswireJazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
PR NewswireJazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
PR NewswireJazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance
PR NewswireJazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance
PR NewswireJazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference
PR NewswireJazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference
PR NewswireJazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025
PR NewswireJazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025
PR NewswireJazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireJazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireJazz Pharmaceuticals Announces CEO Succession Plan
PR NewswireJazz Pharmaceuticals Announces CEO Succession Plan
PR NewswireJazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Societ...
PR NewswireJazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)
PR NewswireJazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
PR NewswireJazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
PR NewswireJazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting
PR NewswireJazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract...
PR NewswireJazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
PR NewswireJazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
PR NewswireJazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
PR NewswireJazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
PR NewswireJazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic H...
PR NewswireJazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024
PR NewswireJazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024
PR NewswirePharmaMar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenan...
PR NewswireJazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance...
PR NewswireJazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
PR NewswireJazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024

Jazz Pharmaceuticals News

Jazz Pharmaceuticals News: auf dieser Seite finden Sie alle Jazz Pharmaceuticals News und Nachrichten zur Jazz Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Jazz Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Jazz Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.